• Revisiting Sumatriptan Metabolism: CYP and MAO Pathways Unco

  2026-07-08

  This study re-evaluates the metabolic fate of sumatriptan, a widely used antimigraine agent, challenging the consensus that its main degradation route is monoamine oxidase A (MAO A)-mediated deamination. Through recombinant enzyme assays, it demonstrates significant contributions from cytochrome P450 isoforms, particularly CYP1A2, CYP2C19, and CYP2D6, to N-demethylation, reshaping our understanding of drug metabolism relevant to neuropharmacology.

• Quizartinib (AC220): Precision FLT3 Inhibition from Biophysi

  2026-07-08

  Explore how Quizartinib (AC220) advances acute myeloid leukemia (AML) research through ultra-selective FLT3 inhibition, quantitative biophysical assays, and translational in vivo models. This article uniquely bridges molecular mechanism, assay design, and clinical relevance for next-generation FLT3-targeted studies.

• Targeting AR and ARv7 in TNBC: EPI-001 Inhibits Metastatic P

  2026-07-07

  This study elucidates the prognostic impact of androgen receptor (AR) and its splice variant ARv7 in triple-negative breast cancer (TNBC), demonstrating their association with poor patient outcomes and increased metastasis. The research further reveals that targeting AR and ARv7 with N-terminal domain inhibitors such as EPI-001 suppresses key metastatic and EMT regulators in TNBC models, opening new avenues for mechanistically targeted research.

• Mavorixafor Hydrochloride: Next-Generation CXCR4 Antagonist

  2026-07-07

  Explore how Mavorixafor hydrochloride, a potent CXCR4 antagonist, is redefining research in immune cell migration and anti-HIV strategies. This article unpacks its advanced mechanism, cross-domain applications, and practical assay considerations.

• Anlotinib Suppresses Angiogenesis via VEGFR2, PDGFRβ, FGFR1

  2026-07-06

  This study demonstrates that anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, effectively inhibits angiogenesis by targeting VEGFR2, PDGFRβ, and FGFR1 signaling pathways. The findings provide mechanistic and comparative evidence for its use as a superior anti-angiogenic agent in preclinical cancer research.

• Ciclesonide in Bench Research: Protocols & Innovations for R

  2026-07-06

  Ciclesonide’s targeted prodrug activation and potent anti-inflammatory effects make it a gold standard for asthma and membrane protein degradation research. Discover practical workflows, troubleshooting strategies, and insights from the latest ERAD-hijacking innovations to unlock new assay possibilities.

• 2',7'-Dichlorofluorescein Diacetate Probe: Precision ROS Ass

  2026-07-05

  Harnessing the 2',7'-dichlorofluorescein diacetate probe enables sensitive, reproducible detection of intracellular oxidative stress, transforming workflows in cancer research and nanomedicine. Learn how optimized protocols and troubleshooting insights unlock robust ROS measurement, with advanced applications demonstrated in cutting-edge nanocarrier studies.

• CENP-E Inhibition, Centromere Integrity, and Mitotic Fidelit

  2026-07-04

  This thought-leadership article explores the mechanistic intersection of centromere-associated protein E (CENP-E) inhibition and centromere integrity, integrating recent insights on CTCF's role in mitosis with the translational utility of GSK-923295. The narrative bridges fundamental cell cycle biology, advanced cancer research, and strategic considerations for translational scientists seeking to dissect mitotic checkpoint mechanisms and optimize preclinical models.

• PXR Activation Drives Liver Regeneration and CYP Induction i

  2026-07-03

  This study demonstrates that activation of the pregnane X receptor (PXR) in rats induces liver enlargement, regeneration, and upregulation of CYP3A1/2 and CYP2C6/11 metabolic activity. These findings clarify the dual role of PXR in hepatic growth and drug metabolism, informing preclinical modeling of liver disease and drug interactions.

• Cy5 amine (non-sulfonated): Protocols and Workflow Guidance

  2026-07-03

  Cy5 amine (non-sulfonated) is a highly photostable, water-insoluble cyanine dye designed for sensitive fluorescence labeling of biomolecules in microscopy, flow cytometry, and molecular imaging workflows. It addresses the need for robust fluorescent labeling where direct aqueous protocols are unsuitable. This reagent should not be used for clinical diagnostics or in workflows requiring water-soluble dyes.

• Rhodamine 123 (chloride): Profiling Transporter Selectivity

  2026-07-02

  Discover how Rhodamine 123 (chloride) enables precise analysis of transporter selectivity and multidrug resistance in cancer research. This in-depth guide explores its mechanistic advantages, advanced assay design, and new insights from recent ABC transporter studies.

• 740 Y-P: Protocol-Driven PI 3-Kinase Activator for Cell Rese

  2026-07-02

  740 Y-P is a potent, cell-permeable PI 3-kinase activator designed for rigorous modulation of the PI3K/AKT signaling pathway in cellular research. It is best suited for applications such as vesicular trafficking studies, neuronal cell survival assays, and apoptosis workflows. Use is not recommended in workflows demanding ethanol solubility or extended long-term solution storage due to its physicochemical constraints.

• Cyanine 5-dCTP for High-Precision DNA Fluorescent Probe Synt

  2026-07-01

  Cyanine 5-dCTP empowers researchers to achieve robust, high-yield fluorescent DNA labeling in advanced enzymatic workflows. By harnessing the strengths of both modern DNA frameworks and optimized protocol parameters, this reagent streamlines nucleic acid detection and imaging with superior sensitivity and reliability.

• DDI2-NFE2L1 Pathway: Proteasome Activation Protects from Fer

  2026-07-01

  This study uncovers how the DDI2-mediated activation of the transcription factor NFE2L1 restores proteasome function and protects cells from ferroptosis, a regulated iron-dependent form of cell death. The findings provide mechanistic insight into the ubiquitin-proteasome system's adaptive response during oxidative stress and highlight DDI2-NFE2L1 as a potential therapeutic target for modulating cell death in disease contexts.

• PD0325901: MEK Inhibitor Workflows for Cancer Research Succe

  2026-06-30

  PD0325901 is redefining precision in RAS/RAF/MEK/ERK pathway inhibition, empowering robust cell cycle and apoptosis studies in oncology. This guide demystifies advanced workflows, troubleshooting, and innovations for maximizing the compound’s impact in cancer research.

452 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page